

February 14, 2026

To,
The Department of Corporate Services,
BSE Limited, Mumbai

Dear Sir,

SUB: OUTCOME OF BOARD MEETING HELD ON FEBRUARY 14, 2026 AND SUBMISSION OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025 WITH LIMITED REVIEW REPORT PURSUANT TO THE PROVISIONS OF REGULATIONS 30 AND 33 (READ WITH PART A OF SCHEDULE III) OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015/ INTEGRATED FILINGS (FINANCIALS).

With reference to the above subject, we would like to inform you that the Board of Directors of Parmax Pharma Limited at its meeting held today i.e. Saturday, February 14, 2026 inter-alia considered and approved Unaudited Standalone Financial Results for the quarter and Nine months ended on December 31, 2025.

In this respect, we are attaching herewith Unaudited Standalone Financial Results for the quarter and nine months ended on December 31, 2025 Limited Review Report of the Statutory Auditors of the Company on the above Result.

The meeting of Board of Directors Commenced at 16:30 PM IST and ended at 17:50 PM IST.

FOR, PARMAX PHARMA LIMITED

Umang Alkesh Gosalia
Managing Director

Statement of Standalone Audited Results for the Quarter and Nine months ended 31.12.2025

(In Rs. Thousands)							
		Quarter Ended			Nine Months Ended		Previous Year Ended 31.03.2025
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	
	(Refer Notes Below)	(Un Audited)	(Un Audited)	(Un Audited)	(Un Audited)	(Un Audited)	(Audited)
I.	Revenue from operations	43257.05	25308.70	62844.41	87988.87	233782.30	282039.58
II.	Other income	72.30	70.16	127.03	209.31	1372.40	395.78
III.	Total Income (I+II)	43329.35	25378.86	62971.44	88198.18	235154.70	282435.36
IV.	Expenses						
	(a) Cost of materials consumed	31277	26780.68	49668.13	66554.23	185768.36	215379.62
	(b) Purchase of stock-in-trade	0.00	0	0		0	0
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-285.05	-1225.88	-4106.53	-254.54	-7507.43	-25.00
	(d) Employee benefits expense	7842.15	6594.57	8437.84	20829.15	24134.85	29883.40
	(e) Finance Costs	2752.99	2400.04	1064.05	7436.90	3478.72	5855.39
	(f) Depreciation and amortisation expense	2666.58	2558.02	4090.67	7637.02	12086.51	10316.94
	(g) Other expenses	6394.92	9055.09	7762.45	21742.92	23185.27	34256.42
	Total expenses (IV)	50648.33	46162.52	66916.61	123945.68	241146.28	295666.77
V	Profit/(Loss) from operations before exceptional items and tax (I-IV)	-7318.98	-20783.66	-3945.16	-35747.61	-5991.57	-13231.41
VI	Exceptional Items	.00	0	0	0	0	10719.64
VII	Profit/ (Loss) before tax (V-VI)	-7318.98	-20783.66	-3945.16	-35747.61	-5991.57	-23951.05
VII	Tax expense:						
	(1) Current tax	0	0	0	0	0	0
	(2) Deferred tax	0	0	0	0	0	-3010.96
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	-7318.98	-20783.66	-3945.16	-35747.61	-5991.57	-20940.10
X	Profit/(loss) from discontinued operations						
XI	Tax expense of discontinued operations	0	0	0	0	0	0
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	0	0	0	0	0	0
XII	Profit (Loss) for the period (IX+XII)	-7318.98	-20783.66	-3945.16	-35747.61	-5991.57	-20940.10
XIV	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0	0	0	0		0
XIV	B. (i) Items that will be reclassified to profit or loss						
	(ii) Income tax relating to items that will be reclassified to profit or loss						
	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	-7318.98	-20783.66	-3945.16	-35747.61	-5991.57	-20940.10
XV	Paid-up equity share capital (Face Value Rs 10)	37413000	37413000	37413000	37413000	37413000	37413000
XV	Earnings per share (for continuing operation & discontinuing operation) (of Rs. 10/- each):						
	(a) Basic	-1.96	-5.56	-1.05	-9.55	-1.60	-5.60
	(b) Diluted	0.00	0.00	0.00	0.00	0.00	0.00

Notes:

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 14th February, 2026 and the same have been audited by the Statutory Auditors in compliance with Regulation 33 of SEBI (LODR) Reg., 2015. The Statutory Auditors have issued an unqualified audit report.
2. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
3. Statement of Un-audited Financial Results of the company for the Quarter and Nine Months ended 31st December, 2025, in the prescribed format under Schedule III of Companies Act, 2013
4. The figures for the previous period have been re-grouped wherever necessary.
5. During the Nine months ended 31.12.2025, Company has not charged the depreciation on the clean room plant and effluent treatment plant and figures of depreciation for the quarter and nine months ended herein above is excluding of depreciation on clean room plant and effluent treatment plant.
6. The Company has lodged the insurance claim to the Insurance Company, wherein surveyor provided insurance provision amounting to Rs. 3.5 crores.

For, Parmax Pharma Limited

Umang Alkesh Gosalia
Managing Director

Place Hadamtala (Rajkot)
Date: 14.02.2026

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

Auditor's Limited Review Report On Unaudited Financial Results

The Board of Directors,

PARMAX PHARMA LIMITED

We have reviewed the accompanying statement of standalone unaudited financial results of **PARMAX PHARMA LTD** ("the Company") for the quarter ended **31st December 2025** ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on **14th February, 2026**. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

Company is awaiting Surveyors Report for fire took place in the month of Dec 2023, in absence of Surveyors Report Claim of Rs. 350 Lacs is not yet submitted with Insurance company.

Company has not provided depreciation on clean room plant and effluent treatment plant considering non usage of these assets.

Based on our review conducted except as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Rajkot

Date: 14.02.2026



For **B. A. SHAH S R MEHTA & Co.**

Chartered Accountants

FRN NO: 128796W

MALAY B SHAH

Partner

M. No. 159526

UDIN: 26159526IHBWPF7405